Flecainide in the treatment and maintenance of ventricular extrasystoles | Ukrainian Medical Journal

Ventricular extrasystole is a common cardiac arrhythmia that can be asymptomatic or lead to serious complications, including tachy-induced cardiomyopathy. Modern treatment involves an individual approach taking into account clinical manifestations, arrhythmia frequency, and the presence of structural changes in the heart. The paper summarizes current data on the use of flecainide (Lixarit), a class IC antiarrhythmic drug that affects the electrophysiological properties of the myocardium and helps reduce the arrhythmic load. Analysis of clinical studies shows that flecainide effectively reduces the frequency of ventricular extrasystoles, improves symptoms, and may positively affect left ventricular function in patients with a high level of extrasystoles. At the same time, it is important to consider the safety profile of the drug, in particular the risk of proarrhythmia and limitations in ischemic heart disease. Flecainide occupies an important place among antiarrhythmic drugs and is a reasonable choice for the treatment of symptomatic ventricular tachycardia in patients without structural heart disease, provided that it is properly selected and monitored.

References

1. Hindricks G., Potpara T., Dagres N. et al. Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2021, 42(40): 4194. doi.org/10.1093/eurheartj/ehab648.
2. Latchamsetty R., Bogun F. Premature ventricular complexes and premature ventricular complex induced cardiomyopathy. Curr. Probl. Cardiol. 2015, 40(9): 379–422. doi.org/10.1016/j.cpcardiol.2015.03.002.
3. Dong Y., Li X., Zheng W. et al. Prevalence and heart rate variability characteristics of premature ventricular contractions detected by 24-hour Holter among outpatients with palpitations in China: a cross-sectional study. BMJ Open. 2022, 12(8): e059337. doi.org/10.1136/bmjopen-2021-059337.
4. Zeppenfeld K., Tfelt-Hansen J., de Riva M. et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur. Heart J. 2022, 43(40): 3997–4126. doi.org/10.1093/eurheartj/ehac262.
5. January C.T., Wann L.S., Calkins H. et al. 2019 AHA/ACC/HRS focused update of the 2014 guideline for atrial fibrillation management. Circulation. 2019, 140(2): e125–e151. doi.org/10.1161/CIR.0000000000000665.
6. Andrikopoulos G.K., Pastromas S., Tzeis S. Flecainide: current status and perspectives in arrhythmia management. World J. Cardiol. 2015, 7(2): 76–85. doi.org/10.4330/wjc.v7.i2.76.
7. Arunachalam K., Patel P. Flecainide. StatPearls. 2026, http://www.ncbi.nlm.nih.gov/books/NBK542291.
8. Moccia F., Brunetti V., Soda T. et al. Store-operated Ca2+ entry as a putative target of flecainide for the treatment of arrhythmogenic cardiomyopathy. J. Clin. Med. 2023, 12(16): 5295. doi.org/10.3390/jcm12165295.
9. Brugada J., Katritsis D. G., Arbelo E. et al. 2019 ESC guidelines for supraventricular tachycardia management. Eur. Heart J. 2020, 41(5): 655–720. doi.org/10.1093/eurheartj/ehz467.
10. Lavalle C., Trivigno S., Vetta G. et al. Flecainide in ventricular arrhythmias: from old myths to new perspectives. J. Clin. Med. 2021, 10(16): 3696. doi.org/10.3390/jcm10163696.
11. Sangpornsuk N., Rungpradubvong V., Tiensantisuk T. et al. Flecainide use in arrhythmic patients who have structural heart disease. Therapeutic Adv. Drug Saf. 2025, 16: 20420986251316462. doi.org/10.1177/20420986251316462.
12. Kotoulas S., Tsiachris D., Botis M. et al. Effect of flecainide in idiopathic premature ventricular contractions and the induced cardiomyopathy. J. Personalized Med. 2025, 15(4): 132. doi.org/10.3390/jpm15040132.
13. Hyman M.C., Mustin D., Supple G. et al. Class IC antiarrhythmic drugs for suspected premature ventricular contraction-induced cardiomyopathy. Heart Rhythm. 2018, 15: 159–163. iris.hunimed.eu/handle/11699/83275.
14. Kojić D., Radunović A., Bukumirić Z. et al. Idiopathic premature ventricular complexes treatment. Clin. Cardiol. 2023, 46(10): 1220–1226. doi.org/10.1002/clc.24090.
15. Ruskin J.N. The cardiac arrhythmia suppression trial (CAST). New Engl. J. Med. 1989, 321(6): 386–388. doi.org/10.1056/NEJM198908103210608.
16. Cardiac Arrhythmia Suppression Trial II Investigators Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. New Engl. J. Med. 1992, 327(4): 227–233. DOI: 10.1056/NEJM199207233270403.
17. Burnham T.S., May H.T., Bair T.L. et al. Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery disease. Am. Heart J. 2022, 243: 127–139. DOI: 10.1016/j.ahj.2021.08.013.
18. Gaine S., Rolland T., Asatryan B. et al. Long-term follow-up data on flecainide use as an antiarrhythmic in arrhythmogenic right ventricular cardiomyopathy. JACC: Clin. Electrophysiol. 2025, 11: 1159–1170. DOI: 10.1016/j.jacep.2025.02.023.
19. Raad M., Yogasundaram H., Oranefo J. et al. Class 1C antiarrhythmics for premature ventricular complex suppression in nonischemic cardiomyopathy with implantable cardioverter-defibrillators. JACC: Clin. Electrophysiol. 2024, 10(5): 846–853. doi.org/10.1016/j.jacep.2024.01.021.
20. Tsiachris D., Kotoulas S., Doundoulakis I. et al. Reappraising use of flecainide for atrial fibrillation and ventricular arrhythmias in structural heart disease patients. Medicina. 2025, 61(10): 1845. doi.org/10.3390/medicina61101845.
21. Tsiachris D., Doundoulakis I., Tsioufis P. et al. Reappraising the role of class Ic antiarrhythmics in atrial fibrillation. Eur. J. Clin. Pharmacol. 2022, 78(6): 1039–1045. doi.org/10.1007/s00228-022-03296-0.
22. Tsioufis P., Tsiachris D., Doundoulakis I. et al. Flecainide vs amiodarone for the cardioversion of atrial fibrillation in the emergency department in patients with coronary artery disease and preserved ejection fraction. EP Europace. 2025, 27(Suppl. S1): euaf085.325. doi: 10.1093/europace/euaf085.325.
23. Tsioufis P., Tsiachris D., Doundoulakis I. et al. Rationale and design of a randomized controlled clinical trial on the safety and efficacy of flecainide versus amiodarone in the cardioversion of atrial fibrillation at the emergency department in patients with coronary artery disease (FLECA-ED). J. Clin. Med. 2023, 12: 3961. DOI: 10.3390/jcm12123961.
24. Merino J.L., Tamargo J., Blomström-Lundqvist C. et al. Practical compendium of antiarrhythmic drugs: a clinical consensus statement of the European Heart Rhythm Association. EP Europace. 2025. doi.org/10.1093/europace/euaf076.
25. Sydorova N. Class IC antiarrhythmic drugs: informed choice. Proceedings of the Latvian Academy of Sciences. 2023, Section B, 77(2): 83–91. doi.org/10.2478/prolas-2023-0012.
26. Ibrahim O.A., Belley-Côté E.P., Um K.J. et al. Single-dose oral anti-arrhythmic drugs for cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials. Europace. 2021, 23(8): 1200–1210. doi.org/10.1093/europace/euab014.
27. Kovacs B., Yakupoglu H.Y., Eriksson U. et al. Medical therapy with flecainide and propafenone in atrial fibrillation: long-term clinical experience in the tertiary care setting. Cardiol. J. 2023, 30(1): 82–90. doi.org/10.5603/CJ.a2022.0116.
28. Przybylski R., Eberly L.M., Alexander M.E. et al. Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease. J. Cardiovascular Electrophysiol. 2023, 34(12): 2545–2551. doi.org/10.1111/jce.16095.
29. Kuridze N., Etsadashvili K., Minadze E. A prospective analysis of the efficacy and safety of ethacizine during premature atrial contractions and premature ventricular contractions. Eur. Heart J. 2024, 45(Suppl. 1): ehae666.3318. doi.org/10.1093/eurheartj/ehae666.3318.
30. Ivanov V.P. Clinical Efficiency and Safety of Ethacizine in Patients With Symptomatic Ventricular Extrasystoles Without Severe Structural Damage of the Myocardium. Ukr. J. Cardiol. 2017, 4: 90–99. ucardioj.com.ua/index.php/UJC/article/view/129.